Condition: Major Depressive Disorder · Sponsor: VistaGen Therapeutics, Inc.
The study will evaluate the safety and efficacy of AV-101.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Diagnosed with MDD, single or recurrent, and currently experiencing a MDE of at least 8 weeks in duration. * Has a history of inadequate response to at least 1 approved antidepressant including at least 1 and no more than 3 during the current depressive episode. * Meet the threshold on the total HAMD-17 score of \> 20 * If female, a status of nonchildbearing potential or use of an acceptable form of birth control. * Body mass index between 18 to 40 kg/m2. * Other criteria may apply Exclusion Criteria: * History of bipolar disorder, schizophrenia or schizoaffective disorders, or any history of psychotic symptoms in the current or previous depressive episodes. * Any Axis I or Axis II Disorder, which at screening is clinically predominant to their MDD or has been predominant to their MDD at any time within 6 months prior to screening. * Women who are pregnant or breastfeeding or a positive pregnancy test at screening or baseline. * Currently taking a prohibited adjunct therapy. Such drugs must be washed out for at least 4 weeks prior to baseline. * Current diagnosis of moderate or severe substance use (including alcohol) disorder (abuse or dependence, as defined by DSM-5), with the exception of nicotine dependence, at screening or within 6 months prior to screening. * In the opinion of the investigator, the subject has a significant risk for suicidal behavior * Has received electroconvulsive therapy, or had repetitive transcranial magnetic stimulation in the current episode. * Has received vagus nerve stimulation at any time prior to screening. * Any current or past history of any physical condition, which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| VistaGen Investigational Site | Garden Grove, California, United States | — |
| VistaGen Investigational Site | Los Angeles, California, United States | — |
| VistaGen Investigational Site | National City, California, United States | — |
| VistaGen Investigational Site | Oakland, California, United States | — |
| VistaGen Investigational Site | San Diego, California, United States | — |
| VistaGen Investigational Site | Temecula, California, United States | — |
| VistaGen Investigational Site | Fort Myers, Florida, United States | — |
| VistaGen Investigational Site | Jacksonville, Florida, United States | — |
| VistaGen Investigational Site | Atlanta, Georgia, United States | — |
| VistaGen Investigational Site | Augusta, Georgia, United States | — |
| VistaGen Investigational Site | Hoffman Estates, Illinois, United States | — |
| VistaGen Investigational Site | Lake Charles, Louisiana, United States | — |
+ 10 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.